Knights of Columbus Asset Advisors LLC Purchases 5,188 Shares of Boston Scientific Corporation $BSX

Key Points

• Knights of Columbus Asset Advisors LLC increased its holdings in Boston Scientific by 8.1%, acquiring 5,188 shares worth approximately $7.4 million during the second quarter.
• Several large investors have recently invested in Boston Scientific, with hedge funds owning 89.07% of the stock, indicating strong institutional interest in the company.
• Boston Scientific reported earnings of $0.75 per share for its latest quarter, surpassing analyst expectations, and set a Q3 2025 EPS guidance of 0.700-0.720.

Knights of Columbus Asset Advisors LLC grew its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,862 shares of the medical equipment provider's stock after acquiring an additional 5,188 shares during the quarter. Knights of Columbus Asset Advisors LLC's holdings in Boston Scientific were worth $7,396,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. 1248 Management LLC purchased a new position in shares of Boston Scientific during the first quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the 1st quarter worth approximately $27,000. Sound Income Strategies LLC boosted its holdings in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group bought a new position in Boston Scientific in the 2nd quarter valued at $37,000. Finally, Activest Wealth Management increased its stake in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock worth $38,000 after purchasing an additional 373 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a "buy (b-)" rating on shares of Boston Scientific in a research note on Saturday, September 27th. Leerink Partners boosted their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the company an "outperform" rating in a research report on Wednesday, October 1st. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. Robert W. Baird boosted their price target on Boston Scientific from $123.00 to $128.00 and gave the company an "outperform" rating in a report on Wednesday, October 1st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $121.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $120.79.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $97.30 on Monday. The firm has a 50 day moving average of $102.93 and a 200 day moving average of $102.06. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $144.17 billion, a price-to-earnings ratio of 57.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.